|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
adults
injection
single dose
children over 9 months
|
|
gptkbp:antigen
|
17D strain
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
1938
|
|
gptkbp:boosterRecommended
|
certain individuals
|
|
gptkbp:brand
|
gptkb:Stamaril
gptkb:YF-VAX
|
|
gptkbp:category
|
live vaccine
|
|
gptkbp:cause
|
mild side effects
rare severe allergic reactions
|
|
gptkbp:contains
|
live attenuated virus
|
|
gptkbp:contraindication
|
immunocompromised individuals
infants under 6 months
people with severe egg allergies
|
|
gptkbp:developedBy
|
gptkb:Max_Theiler
|
|
gptkbp:discoveredBy
|
gptkb:Max_Theiler
|
|
gptkbp:documentedIn
|
International Certificate of Vaccination or Prophylaxis
|
|
gptkbp:duration
|
lifelong in most cases
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Yellow fever vaccine
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:NobelPrizeYear
|
Max Theiler won Nobel Prize in 1951 for its development
|
|
gptkbp:notRecommendedFor
|
breastfeeding women unless at high risk
pregnant women unless at high risk
|
|
gptkbp:prevention
|
gptkb:yellow_fever
|
|
gptkbp:producedBy
|
gptkb:Sanofi_Pasteur
gptkb:Bio-Manguinhos
gptkb:Chumakov_Institute
|
|
gptkbp:providesImmunityFor
|
at least 10 years
|
|
gptkbp:recommendation
|
travelers to endemic areas
|
|
gptkbp:requires
|
some countries in Africa
some countries in South America
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:usedIn
|
mass vaccination campaigns
|
|
gptkbp:WHOPrequalified
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Yellow_Fever
|
|
gptkbp:bfsLayer
|
5
|